Drug

Thioguanine

Established medicine

ClassInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorResearchOngoing clinical research

Also known as 2-Amino 6MP, 2-Amino-6-mercaptopurine, 2-Amino-6-merkaptopurin, 2-Amino-6-purinethiol+18 more

2-Amino 6MP, 2-Amino-6-mercaptopurine, 2-Amino-6-merkaptopurin, 2-Amino-6-purinethiol, 2-Aminopurin-6-thiol, 2-Aminopurine-6(1H)-thione, 2-Aminopurine-6-thiol, 6-Mercapto-2-aminopurine, 6-Mercaptoguanine, 6-TG, 6-Thioguanine, 6TG, TG, Tabloid, ThG, Tioguanin, Tioguanina, Tioguanine, Tioguaninum, 2-Amino-1,7-dihydro-6H-purine-6-thione, 2-amino-1,9-dihydropurine-6-thione, 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI).

RxNorm10485 ChEMBLCHEMBL727 ATCL01BB03UNIIWIX31ZPX66

Active clinical trials

Protein targets

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

Clinical trial2026-08-07Results expected Q4 2028 · ClinicalTrials.gov

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Clinical trial2026-07-30Results expected Q3 2027 · ClinicalTrials.gov

An International Phase 2 Study of Chemotherapy and Tyrosine Kinase Inhibitors With Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia

Clinical trial2026-07-28Results expected Q4 2030 · ClinicalTrials.gov

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Clinical trial2026-07-02Results expected Q1 2027 · ClinicalTrials.gov

Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL)

Clinical trial2026-06-29Results expected Q3 2026 · ClinicalTrials.gov

Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma

Clinical trial2026-06-23Results posted · ClinicalTrials.gov

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Clinical trial2026-06-22Results expected Q1 2032 · ClinicalTrials.gov

A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Clinical trial2026-06-17Results expected Q3 2035 · ClinicalTrials.gov

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Clinical trial2026-06-17Results posted · ClinicalTrials.gov

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Clinical trial2026-06-17Results expected Q3 2026 · ClinicalTrials.gov

A Phase II Randomized Study of Blinatumomab With or Without Revumenib for Patients With KMT2A-Translocation B-Cell Acute Lymphoblastic Leukemia (ALL)/ Acute Leukemia With Ambiguous Lineage (ALAL) With Persistent Measurable Residual Disease (MRD)

Clinical trial2026-06-09Results expected Q2 2031 · ClinicalTrials.gov

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Clinical trial2026-06-03Results posted · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Thioguanine

Aliases & brands

2-Amino 6MP2-Amino-6-mercaptopurine2-Amino-6-merkaptopurin2-Amino-6-purinethiol2-Aminopurin-6-thiol2-Aminopurine-6(1H)-thione2-Aminopurine-6-thiol6-Mercapto-2-aminopurine6-Mercaptoguanine6-TG6-Thioguanine6TGTGTabloidThGTioguaninTioguaninaTioguanineTioguaninum2-Amino-1,7-dihydro-6H-purine-6-thione2-amino-1,9-dihydropurine-6-thione6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI)

RxNorm CUI

10485

ChEMBL ID

CHEMBL727

ATC codes

L01BB03

UNII

WIX31ZPX66

Primary mechanism

Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor